tubulin tyrosine ligase like 2Genealiases: C6orf104 · NYD-TSPG · dJ366N23.3
Q-omics provides the consensus-scored TTLL2 profile across patient tissues and cancer cell-line models. TTLL2 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in PAAD. Among the 18 cancer types available for tumor–normal comparison, TTLL2 is differentially expressed in 10, with the highest sampling consensus in KICH. Additionally, TTLL2 protein abundance shows 22,354 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight PAAD, KICH, and GBM as cancer lineages where TTLL2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TTLL2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TTLL2 survival associations across molecular data types. TTLL2 RNA expression shows survival associations in the most cancer types (18), followed by mutation status (5) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TTLL2 RNA expression–survival associations across cancer types. High TTLL2 expression shows unfavorable associations in ACC, but favorable associations in PAAD, READ, LUAD, UCEC and KIRP. The PAAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify PAAD as the clearest survival context for TTLL2 RNA expression.
This table summarizes TTLL2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 6. The strongest signals are observed in KICH for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for TTLL2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TTLL2 shows lower tumor expression in KICH and THCA and higher tumor expression in COAD, STAD, KIRP and LUAD. The KICH box plot shows higher TTLL2 RNA expression in normal versus tumor tissue (log2 FC = −0.234, t-test p < 0.001).
This table shows molecular features associated with TTLL2 in patient tissues and cancer cell lines. In patient samples, TTLL2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, TTLL2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BLOOD_Leukemia.
